This could also explain why combined anti-CTLA-4 + anti-PD-1 checkpoint blockade is particularly effective since anti-CTLA-4 would deplete Tregs whilst anti-PD-1 would directly dampen tumor glycolysis by inhibiting the mTOR pathway (159). The gene discussed is RPL17; the disease is neoplasm.